Success Metrics

Clinical Success Rate
37.5%

Based on 3 completed trials

Completion Rate
38%(3/8)
Active Trials
0(0%)
Results Posted
167%(5 trials)
Terminated
5(63%)

Phase Distribution

Ph phase_1
1
13%
Ph phase_3
3
38%
Ph phase_2
3
38%

Phase Distribution

1

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
3(42.9%)
Phase 3Large-scale testing
3(42.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

37.5%

3 of 8 finished

Non-Completion Rate

62.5%

5 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(3)
Terminated(5)

Detailed Status

Terminated5
Completed3

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
37.5%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (14.3%)
Phase 23 (42.9%)
Phase 33 (42.9%)

Trials by Status

completed338%
terminated563%

Recent Activity

0 active trials
Showing 5 of 8
terminatedphase_2

Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab

NCT00916617
terminatedphase_3

Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients

NCT00676143
terminatedphase_3

Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients

NCT00667810
terminated

Retrieval of Patient Information After Discontinuation

NCT01658722
completedphase_1

Study Evaluating Single Ascending Doses of AAB-001 Vaccine SAD Japanese Patients With Alzheimers Disease

NCT00397891
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT00916617Phase 2

Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab

Terminated
NCT00676143Phase 3

Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients

Terminated
NCT00667810Phase 3

Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients

Terminated
NCT01658722

Retrieval of Patient Information After Discontinuation

Terminated
NCT00397891Phase 1

Study Evaluating Single Ascending Doses of AAB-001 Vaccine SAD Japanese Patients With Alzheimers Disease

Completed
NCT00937352Phase 3

A Long-Term Safety and Tolerability Study in Subjects With Mild to Moderate Alzheimer's Disease

Terminated
NCT00663026Phase 2

Study Evaluating Bapineuzumab In Alzheimer Disease Subjects

Completed
NCT00112073Phase 2

AAB-001 in Patients With Mild to Moderate Alzheimer's Disease

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8